Geron (GERN) EBITDA Margin (2010 - 2026)

Geron (GERN) posted EBITDA Margin of 0.3% for Q1 2026, down 98.42% sequentially from 19.35% in Q4 2025, and up 4248.0% YoY from 0.01% in Q1 2025.

Geron (GERN) EBITDA Margin (2010 - 2026) Analysis & Trends

Geron has reported EBITDA Margin for 17 years, with the latest figure at 0.3% in Q1 2026.

Quarterly EBITDA Margin rose 4248.0% year-over-year to 0.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 321.6% (up 1586.0% YoY) and the FY2025 annual result came in at 1781.89%, up 3303414.0% from the prior year.
EBITDA Margin slipped to 0.3% in Q1 2026 per GERN's latest filing, from 19.35% in the prior quarter.
Over five years, EBITDA Margin peaked at 25368.69% in Q4 2023 and troughed at 190914.29% in Q1 2023.
A 5-year average of 30351.09% and a median of 7860.88% in 2024 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 16760128 bps in 2023, then surged 17244915 bps in 2024.
Over 5 years, EBITDA Margin stood at 40729.13% in 2022, then soared by 162 bps to 25368.69% in 2023, then sank by 100 bps to 69.24% in 2024, then slumped by 72 bps to 19.35% in 2025, then slumped by 98 bps to 0.3% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 0.3%, 19.35%, and 29.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.94 Bn	132.09 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.59 Bn	78.60 Bn	3.93 Bn	30.15%
3	Argenx Se	65.67 Bn	60.49 Bn	1.37 Bn	32.54%
4	Moderna	57.81 Bn	52.67 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.41 Bn	10.02 Bn	668.28 Mn	-35.57%
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	19.75%
10	Geron	1.05 Mn	-299.80 Mn	-	-21.74%

Download Data